Grace & White Inc. NY reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 43,200 shares of the company’s stock after selling 4,266 shares during the period. Grace & White Inc. NY’s holdings in Johnson & Johnson were worth $5,242,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Financial Gravity Wealth Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $105,000. FNY Investment Advisers LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $117,000. Princeton Capital Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $141,000. Smart Portfolios LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $150,000. Finally, Live Your Vision LLC increased its holdings in Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after purchasing an additional 502 shares in the last quarter. 66.67% of the stock is owned by hedge funds and other institutional investors.

In related news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by corporate insiders.

Shares of NYSE JNJ opened at $139.05 on Friday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a market capitalization of $374.16 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The firm had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.59%. Johnson & Johnson’s payout ratio is 49.32%.

A number of equities analysts have recently weighed in on the company. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Credit Suisse Group boosted their target price on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday. Raymond James boosted their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $141.54.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Risk Tolerance

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.